Healio Minute Podcast, DME/Retina Edition: Top Headlines - Week of August 5, 2024
Click Here to Manage Email Alerts
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more.
Read the full coverage here:
Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
References:
Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.
Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Collapse
Click Here to Manage Email Alerts
